Pages that link to "Q48103864"
Jump to navigation
Jump to search
The following pages link to Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its a (Q48103864):
Displaying 39 items.
- Experimental treatment of antipsychotic-induced movement disorders (Q26740354) (← links)
- Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development (Q26853509) (← links)
- Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents (Q28140526) (← links)
- Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs (Q28305100) (← links)
- In vivo comparison of two 5-HT1A receptors agonists alnespirone (S-20499) and buspirone on locus coeruleus neuronal activity (Q33963424) (← links)
- Regulation by 5-HT1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex (Q33973888) (← links)
- Effect of antidepressants on melatonin metabolite in depressed patients. (Q34012324) (← links)
- Role of serotonin in central dopamine dysfunction. (Q34022787) (← links)
- A new strategy for antidepressant prescription (Q34371007) (← links)
- Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist. (Q34994489) (← links)
- Pharmacological Treatment of Cannabis Dependence (Q35210350) (← links)
- Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis (Q35892818) (← links)
- On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal (Q38110358) (← links)
- Both acute and chronic buspirone treatments have different effects on regional 5-HT synthesis in Flinders Sensitive Line rats (a rat model of depression) than in control rats (Q41814847) (← links)
- Quetiapine and Buspirone Both Elevate Cortical Levels of Noradrenaline and Dopamine In vivo, but Do Not have Synergistic Effects. (Q42325246) (← links)
- Reduced anxiety and depression-like behaviors in mice lacking GABA transporter subtype 1. (Q42505466) (← links)
- Quetiapine anxiolytic-like effect in the Vogel conflict test is serotonin dependent (Q42923008) (← links)
- The effects of acute treatment with escitalopram on the different stages of contextual fear conditioning are reversed by atomoxetine (Q42949858) (← links)
- 5-HT(1A) receptor mutant mice exhibit enhanced tonic, stress-induced and fluoxetine-induced serotonergic neurotransmission (Q43572910) (← links)
- Effect of chronic administration of flesinoxan and fluvoxamine on freezing behavior induced by conditioned fear (Q43774266) (← links)
- Behavioural and biochemical studies of citalopram and WAY 100635 in rat chronic mild stress model (Q43921759) (← links)
- Possible alteration of tryptophan metabolism following repeated administration of sertraline in the rat brain (Q44237510) (← links)
- Buspirone-induced antinociception is mediated by L-type calcium channels and calcium/caffeine-sensitive pools in mice (Q44293185) (← links)
- The 5-HT1A receptor and behavioral stimulation in the rat: effects of 8-OHDPAT on spontaneous and cocaine-induced behavior (Q44914232) (← links)
- Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex. (Q45071449) (← links)
- Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism (Q45145553) (← links)
- Orexin A promotes histamine, but not norepinephrine or serotonin, release in frontal cortex of mice. (Q45233267) (← links)
- In-vivo effects of the 1,2,4-piperazine derivatives MM5 and MC1, putative 5-HT agonists, on dopamine and serotonin release in rat prefrontal cortex (Q45273767) (← links)
- Effect of risperidone on the fluoxetine-induced changes in extracellular dopamine, serotonin and noradrenaline in the rat frontal cortex (Q45757639) (← links)
- Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. (Q45921170) (← links)
- Fluoxetine inhibits corticotropin-releasing factor (CRF)-induced behavioural responses in rats (Q46296982) (← links)
- Neurokinin1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: a neurochemical, electrophysiological, and behavioral characterization (Q46335868) (← links)
- Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus (Q46640346) (← links)
- Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats. (Q46923390) (← links)
- Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex (Q46978352) (← links)
- The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders (Q47382890) (← links)
- Human motoneurone excitability is depressed by activation of serotonin 1A receptors with buspirone (Q48032494) (← links)
- In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain (Q48292762) (← links)
- Therapeutic doses of buspirone block D3 receptors in the living primate brain. (Q52304391) (← links)